after joining the study, a baseline visit is scheduled. during this visit, measurements of daytime sleepiness and cataplexy are recorded, and questionnaires such as the epworth sleepiness scale are completed.

based on the baseline data, you are randomly assigned to receive either alks 2680 tablets or a matching placebo tablet.

on the day following randomization, you begin taking the assigned tablet.

the tablet is taken oral (by mouth) and is formulated as a tablet.

the specified dose is 00 mg per tablet.

the medication is taken daily for a period of up to 12 weeks, unless instructed otherwise by the study team.

throughout the 12‑week treatment period, you attend scheduled clinic visits.

at each visit, safety checks are performed, side effects are reviewed, and you may complete additional questionnaires.

objective tests such as the maintenance of wakefulness test may be administered to assess alertness.

at the end of week 12, a comprehensive assessment is conducted.

the primary outcome measured is the change in the epworth sleepiness scale score from baseline.

secondary outcomes include the change in mean sleep latency on the maintenance of wakefulness test, the weekly cataplexy rate, and other patient‑reported outcomes.

after the week 12 assessment, the study medication is discontinued.

a final evaluation is performed to record any remaining effects and to ensure safety.

study data are then compiled for analysis.